ABSTRACT
Objective:To explore the application value of diagnosis related groups(DRG) technology in clinical application management of antibiotics for inpatients.Methods:Inpatients discharged from a tertiary general from April to June 2020 were selected as the study objects. DRG grouping data were obtained from the provincial DRG-based hospital quality management and performance evaluation platform, and antibiotics application data were extracted from the hospital information system of the hospital in question. Based on the DRG group, a descriptive statistical analysis was conducted on the overall situation of antibiotics application and the applications between departments and physicians in different time periods.Results:A total of 8 263 discharged patients were included, involving 491 groups of DRG, with 4 193 of whom treated with antibiotics and 417 groups of DRG involved. The antibiotics use density(AUD)was significantly different among different DRG groups, with the maximum being 290 DDDs/100 person days(EM18C group)and the minimum 0.21 DDDs/100 person days(FM15B group). Analysis of the NS06Z group, which had the largest number of cases from April to June, found that the utilization rate of antibiotics changed little with time. Analysis of the typical case group EM11A, found that the AUD and utilization rate of antibiotics were too high in some departments and physicians. Some departments and physicians also presented the problem of high rate of combined drug use.Conclusions:DRG can scientifically evaluate the clinical application of antibiotics in inpatients, identify the key points of clinical application management of antibiotics in inpatients, and contribute to fine management of clinical application of antibiotics in inpatients.
ABSTRACT
OBJECTIVE:To evaluate the effects of PDCA cycle management method on clinical application of Fat-soluble vita-min for injection (Ⅱ). METHODS:By retrospective analysis,500 discharge medical records of Fat-soluble vitamin for injection (Ⅱ)were collected from our hospital during Jul.-Aug. in 2015(before intervention),Sep.-Oct. in 2015(after first intervention cy-cle),Nov.-Dec. in 2015(after second intervention cycle),respectively. RESULTS:After 2 PDCA cycles,the proportion Fat-solu-ble vitamin injection (Ⅱ) use without indication decreased from 65.4% to 39.2%;the reasonable rate of drug dosage increased from 53.2% to 97.2%,and that of usage increased from 96.4% to 99.8%;the reasonable rate of medication course increased from 69.6% to 96.6%;the reasonable rate of the clinical application of Fat-soluble vitamin injection (Ⅱ) increased from 18.8% to 56.4%,with statistical significance (P<0.05). CONCLUSIONS:PDCA cycle can effectively promote the clinical reasonable of Fat-soluble vitamin for injection(Ⅱ).